- Camurus’ second CRL for acromegaly drug; Teva details workforce cutsPlus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer.…Endpoints · 1mo ago↗ source
- Biopharma pay report: Top-paid CSOs, CMOs of 2025Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News…Endpoints · 1mo ago↗ source
- Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamParabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...